BPG is committed to discovery and dissemination of knowledge
Articles in Press
1/21/2026 7:55:45 AM | Browse: 2 | Download: 0
Publication Name World Journal of Hepatology
Manuscript ID 115539
Country Peru
Category Gastroenterology & Hepatology
Manuscript Type Minireviews
Article Title Dyslipidemia in liver cirrhosis: Pathophysiology and emerging therapeutic approaches
Manuscript Source Invited Manuscript
All Author List Jenyfer M Fuentes-Mendoza, Marcio J Concepción-Zavaleta, Jeny J Mendoza-Godoy, Luis A Concepción-Urteaga, Carlos O Martínez-Gutiérrez and José Paz-Ibarra
Funding Agency and Grant Number
Corresponding Author Marcio J Concepción-Zavaleta, Grupo de Investigación en Neurociencias, Metabolismo, Efectividad Clínica y Salud Pública, Universidad Científica del Sur, 19 Panamericana Sur, Villa El Salvador, Lima 15067, Peru. mconcepcion@cientifica.edu.pe
Key Words Liver cirrhosis; Dyslipidemia; Hepatic lipid metabolism; Lipoprotein dysfunction; Cholestasis; Cardiometabolic risk
Core Tip Dyslipidemia in liver cirrhosis reflects fundamental alterations in hepatic lipid biology, including impaired apolipoprotein synthesis, defective lipoprotein export, receptor downregulation, and cholestasis-driven accumulation of atypical particles such as lipoprotein X and lipoprotein Z. These molecular disturbances generate stage-specific lipid phenotypes that challenge conventional cardiovascular risk assessment and drug targeting. Non-statin lipid-lowering agents provide mechanistically informative tools to probe these disrupted pathways; however, their effects in cirrhosis remain largely defined by pharmacologic rationale rather than direct clinical evidence. Understanding how disease stage and etiology reshape hepatic lipid handling is essential for rational application and future development of lipid-modifying strategies in cirrhotic populations.
Citation Fuentes-Mendoza JM, Concepción-Zavaleta MJ, Mendoza-Godoy JJ, Concepción-Urteaga LA, Martínez-Gutiérrez CO, Paz-Ibarra J. Dyslipidemia in liver cirrhosis: Pathophysiology and emerging therapeutic approaches. World J Hepatol 2026; In press
Received
2025-10-20 01:27
Peer-Review Started
2025-10-20 01:27
First Decision by Editorial Office Director
2025-10-30 09:17
Return for Revision
2025-10-30 09:17
Revised
2025-11-12 01:00
Publication Fee Transferred
Second Decision by Editor
2026-01-21 02:38
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director
2026-01-21 07:55
Articles in Press
2026-01-21 07:55
Edit the Manuscript by Language Editor
Typeset the Manuscript
ISSN 1948-5182 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com